All In Biotech

Drug Trial Radar · NCT00546637

Fesoterodine "add-on" Male Overactive Bladder Study

A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Fesoterodine As An "Add-On" Therapy In Men With Persistent Overactive Bladder Symptoms Under Monotherapy Of Alpha Blocker For Lower Urinary Tract Symptoms.

Last checked: Nov 20, 2026Latest source record: Feb 18, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 947 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

947

Actual

Start

Nov 2007

Primary completion

Feb 2009

Study completion Feb 2009

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Oct 19, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Male only, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of fesoterodine on overactive bladder symptom improvement when added to ongoing alpha blocker treatment.

Conditions

  • Overactive Bladder Syndrome

Interventions

  • FesoterodineDrug

    Fesoterodine 4mg or 8mg

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Numerical Change From Baseline in Micturition-Related Urgency Episodes Per 24 Hours at Week 12Time frame: Baseline, Week 12

Locations

137 sites in 19 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    Gilbert, Arizona

  • Pfizer Investigational Site

    Gilbert, Arizona

  • Pfizer Investigational Site

    Litchfield Park, Arizona

  • Pfizer Investigational Site

    Mesa, Arizona

  • Pfizer Investigational Site

    Phoenix, Arizona

  • Pfizer Investigational Site

    Tucson, Arizona

  • Pfizer Investigational Site

    La Mesa, California

  • Pfizer Investigational Site

    Newport Beach, California

  • Pfizer Investigational Site

    San Bernardino, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    Aurora, Colorado

  • Pfizer Investigational Site

    Denver, Colorado

  • Pfizer Investigational Site

    Jupiter, Florida

  • Pfizer Investigational Site

    Orange City, Florida

  • Pfizer Investigational Site

    West Palm Beach, Florida

  • Pfizer Investigational Site

    Dunwoody, Georgia

  • Pfizer Investigational Site

    Evansville, Indiana

  • Pfizer Investigational Site

    Jeffersonville, Indiana

  • Pfizer Investigational Site

    Newburgh, Indiana

  • Pfizer Investigational Site

    Des Moines, Iowa

  • Pfizer Investigational Site

    Iowa City, Iowa

  • Pfizer Investigational Site

    Baltimore, Maryland

  • Pfizer Investigational Site

    Owings Mills, Maryland

  • Pfizer Investigational Site

    Watertown, Massachusetts

  • Pfizer Investigational Site

    Flint, Michigan

  • Pfizer Investigational Site

    Saint Clair Shores, Michigan

  • Pfizer Investigational Site

    Troy, Michigan

  • Pfizer Investigational Site

    Utica, Michigan

  • Pfizer Investigational Site

    West Bloomfield, Michigan

  • Pfizer Investigational Site

    West Bloomfield, Michigan

  • Pfizer Investigational Site

    Minneapolis, Minnesota

  • Pfizer Investigational Site

    Omaha, Nebraska

  • Pfizer Investigational Site

    Sewell, New Jersey

  • Pfizer Investigational Site

    Albany, New York

  • Pfizer Investigational Site

    Garden City, New York

  • Pfizer Investigational Site

    Kingston, New York

  • Pfizer Investigational Site

    New York, New York

  • Pfizer Investigational Site

    Poughkeepsie, New York

Showing 40 of 137 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.